Amgen Inc. (AMGN) stock rallied over 0.42% intraday to trade at $247.29 a share on NASDAQ. The stock opened with a gain of 0.34% at $245 and touched an intraday high of $247.74, rising 0.42% against the last close of $246.25. The stock went to a low of $244.325 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue26.32 Billion
5Y Sales Change2.5%
Fiscal Year Ends2021-12-30
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behcet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Amgen Inc. (NASDAQ: AMGN) stock price is $247.29 as of the last check on Monday, August 8. During the trading session, AMGN stock reached the peak price of $247.74 while $244.325 was the lowest point it dropped to.
The NASDAQ listed AMGN is part of Biotechnology industry that operates in the broader Health Care sector. Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Mr. Robert A. Bradway
Chairman, CEO & Pres
Mr. Peter H. Griffith
Exec. VP & CFO
Mr. Esteban Santos
Exec. VP of Operations
Dr. David M. Reese M.D.
Exec. VP of R&D
AMGN stock traded closed the last session at $247.29, which is $1.039999999999992 or 0.42233502538070744% lower than its previous close of $246.25. AMGN's current trading price is 24.49% lower than its 52-week high of $258.45 where as its distance from 52-week low of 198.64% is -4.32%.
Number of AMGN employees currently stands at -. AMGN operates from One Amgen Center Drive, Thousand Oaks, CA 91320-1799, United States.
Official Webiste of $AMGN is: https://www.amgen.com
AMGN stock volume for the day was 2,784,544 shares while in the previous session number of AMGN shares traded was 2,784,087 . The average number of AMGN shares traded daily for last 3 months was 3.13 Million.
The percentage change in AMGN stock occurred in the recent session was 0.42233502538070744% while the dollar amount for the price change in AMGN stock was $1.039999999999992.
In the recent session, the day high for AMGN stock was $247.74 while the low for AMGN stock touched on the day was $244.325.
The market value of AMGN currently stands at 132.49 Billion with its latest stock price at $247.29 and 548 Million of its shares outstanding.